LMR Partners’s Entrada Therapeutics TRDA Stock Holding History

LMR Partners’s Portfolio TRDA Stock Details TRDA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q2	–	Sell	-13,023	Closed	-$189K	–	1114
2023 Q1	$189K	Buy	+13,023	New	+$174K	﹤0.01%	865

Other funds holding TRDA

BBA

Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return

MAM

MPM Asset Management Boston, Massachusetts $44.5M AUM 47.28% 1-Year Est. Return

5VM

5AM Venture Management San Francisco, California $288M AUM 313.93% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Redmile Group San Francisco, California $1.49B AUM 208.7% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

StepStone Group La Jolla, California $2.16B AUM 20.11% 1-Year Est. Return

TCG Crossover Management Palo Alto, California $4.16B AUM 983.43% 1-Year Est. Return

LMR Partners's TRDA Position: Q2 2023 in Review

LMR Partners sold out of Entrada Therapeutics (TRDA) in Q2 2023, closing a stake of 13,023 shares — an estimated $189K sold.

LMR Partners first reported a position in TRDA in Q1 2023 and held it in 1 quarter. The position peaked at $189K in Q1 2023. 56 funds tracked by Wall St. Rank hold TRDA as of Q2 2023.

LMR Partners reported no remaining Entrada Therapeutics position as of Q2 2023 after selling out during the quarter.
LMR Partners sold 13,023 Entrada Therapeutics shares in Q2 2023, an estimated $189K.
LMR Partners first reported a position in Entrada Therapeutics in Q1 2023 and held it in 1 quarter.
LMR Partners's Entrada Therapeutics position peaked at $189K in Q1 2023.
56 funds tracked by Wall St. Rank held Entrada Therapeutics as of Q2 2023.

Based on LMR Partners's 13F filing for Q2 2023, filed 14 Aug 2023.